2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Assays, Imaging, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Non-Biological Therapies, Pharmacology, Women’s Health, Adverse Events, Biological Processes, Pathogenesis, Hematopoiesis, Immune Mechanism, Metabolism, Clinical Practice (Health Services and Quality), Patient Safety, Quality Improvement, Value, Diseases, Bleeding and Clotting, Bleeding Disorders, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Myeloid Malignancies, Metabolic Disorders, Iron Deficiency, Iron Overload, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

2883 TMPRSS6 inhibition by REGN7999 reduces iron accumulation in immune cells in a mouse model of beta-thalassemia

Heinrich E. Lob, PhD, Larisa Ivanova2, Beth Crowell3, Aris N. Economides, PhD4, Sarah J. Hatsell, PhD5
1 Regeneron Pharmaceuticals, Tarrytown, New York, United States
2 Regeneron Pharmaceuticals, Tarrytown, New York, United States
3 Regeneron Pharmaceuticals, Tarrytown, New York, United States
4 Regeneron Pharmaceuticals, Tarrytown, New York, United States
5 Regeneron Pharmaceuticals, Tarrytown, New York, United States

Beta-thalassemia is an inherited disorder caused by loss-of-function mutations in the beta-globin gene, resulting in ineffective erythropoiesis and systemic iron overload. Chronic iron accumulation contributes to clinically significant complications, including liver fibrosis, type 2 diabetes, malignancy, and cardiac toxicity. Transmembrane serine protease 6 (TMPRSS6) is a negative regulator of hepcidin, the central hormone controlling iron homeostasis. We previously developed REGN7999, a monoclonal antibody targeting TMPRSS6, and demonstrated that REGN7999 reduces liver iron loading and improves erythropoiesis in Hbbth3/+ mice, a model of beta-thalassemia. Unexpectedly, we also observed increased splenic iron after 8 weeks of treatment (8 doses). Because elevated iron has been linked to aberrant immune activation, we investigated whether REGN7999 alters immune cell iron accumulation and activation in this model. Hbbth3/+mice were treated with REGN7999 (10 mg/kg, subcutaneously) or an isotype control, and iron levels, immune cell populations, activation markers, and cytokines were assessed in spleen and blood. Splenic immune profiling showed no change in the frequency of B or T cells in Hbbth3/+ mice, while F4/80+ macrophages were significantly increased; this macrophage expansion was normalized after 8 weeks of REGN7999 treatment. B cells, T cells, and macrophages isolated from Hbbth3/+ mice accumulated more ferrous iron than cells from wild-type controls or REGN7999-treated Hbbth3/+ mice. In the circulation, immune cell frequencies, including T cells, B cells, and monocytes, were comparable between Hbbth3/+ mice and wild-type controls. However, CD4+T cells from Hbbth3/+ mice showed increased CD80 expression, consistent with enhanced T cell activation. Serum tumor necrosis factor alpha (TNF-α) was also significantly elevated. REGN7999 prevented this T cell activation phenotype and normalized serum TNF-α levels. Notably, all immune cell populations examined in Hbbth3/+ mice showed increased ferrous iron loading, which was reduced after REGN7999 treatment.


To further evaluate the relationship between iron loading and immune activation, we exposed Jurkat T cells to elevated ferrous or ferric iron levels in vitro. We found that only ferric ammonium citrate, but not holo-transferrin, increased secretion of pro-inflammatory cytokines, including TNF-β and granulocyte-macrophage colony-stimulating factor.

Together, these findings support emerging evidence that labile iron accumulation in immune cells contributes to inflammatory responses and autoimmune disease. They further suggest that, in beta-thalassemia, elevated ferrous iron may promote immune activation and strategies reducing the iron overload may also reduce immune cell iron loading and associated inflammatory activation.

Heinrich E. Lob, PhD: Regeneron Pharmaceuticals - Stock (publicly traded); Regeneron Pharmaceuticals - Current Employment